Today: 7 February 2026
Subscribe

Why Opendoor stock is jumping today: Trump’s $200 billion mortgage-bond buy order

Why Opendoor stock is jumping today: Trump’s $200 billion mortgage-bond buy order

NEW YORK, Jan 9, 2026, 11:51 EST — Regular session Opendoor Technologies Inc shares rose 20.5% to $7.75 in late morning trading on Friday, after swinging between $6.82 and $7.83. Volume topped 90 million shares, well above a typical day for the thinly profitable homebuying sector. The rally tracked a broader move in housing-linked names after President Donald Trump said he was ordering his representatives to buy $200 billion in mortgage bonds, a step he said would push down mortgage rates and monthly payments. Mortgage-backed securities, or MBS, are bonds backed by pools of home loans; buying them can lift
9 January 2026
··
Westlake (WLK) stock steadies near $80 after a 7% jump as analysts reset targets

Westlake (WLK) stock steadies near $80 after a 7% jump as analysts reset targets

New York, Jan 9, 2026, 11:45 EST — Regular session Westlake Corp shares added to Friday’s gains, keeping Thursday’s sharp rebound going as investors digested new analyst target changes. The stock was up about 0.8% at $80.20 after jumping 6.8% on Thursday, and it traded between $78.49 and $81.19 during the session. (StockAnalysis) Westlake is worth watching here: it’s caught between U.S. housing and global industrial demand, two forces that have whipsawed chemical makers in recent quarters. The Houston-based group sells chemicals, polymers and building products, which keeps the stock exposed to swings in construction activity and commodity pricing. (Business
9 January 2026
···
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

New York, January 9, 2026, 12:09 EST — Regular session Merck & Co Inc shares were up about 0.4% at $111.41 on Friday as investors weighed a report that the drugmaker is in talks to buy cancer biotech Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped nearly 16% in extended trading on Thursday after the Financial Times report, which said talks were not final and could still take weeks, with other large drugmakers still circling; Merck and Revolution did not respond to requests for comment. The potential acquisition would be the biggest in
9 January 2026
····
Robinhood stock edges higher after Argus starts coverage; CEO share sale filing hangs over

Robinhood stock edges higher after Argus starts coverage; CEO share sale filing hangs over

New York, Jan 9, 2026, 11:51 EST — Regular session Robinhood Markets, Inc. shares ticked up on Friday after Argus initiated coverage of the online broker with a buy rating and a $145 price target, giving bulls fresh copy even as insider selling stayed in view. (MarketScreener) The move came with U.S. stocks broadly higher after a softer-than-expected December jobs report kept bets on interest-rate cuts alive, giving higher-beta financial names some air. Traders were also keeping an eye on an expected U.S. Supreme Court decision on President Donald Trump’s tariffs, a possible source of sudden volatility. (Reuters) Barclays, meanwhile,
9 January 2026
··
Figure Technology Solutions stock slips after a $62 target hike — what traders watch nextFigureFigure Technology Solutions stock slips after a $62 target hike — what traders watch next

Figure Technology Solutions stock slips after a $62 target hike — what traders watch nextFigureFigure Technology Solutions stock slips after a $62 target hike — what traders watch next

New York, Jan 9, 2026, 11:46 EST — Regular session Shares of Figure Technology Solutions (FIGR) fell about 1.5% to $57.50 in late-morning trading on Friday, easing a day after Keefe, Bruyette & Woods lifted its price target on the stock. The shares traded between $56.27 and $58.97. The move matters because FIGR has become a fast-moving name in early 2026, drawing momentum traders and fresh analyst attention after a sharp run. Zacks Equity Research wrote on Friday that the stock has gained about 43% so far this year, helped by upward revisions to earnings estimates. Figure operates what it
9 January 2026
·
Exxon Mobil (XOM) stock ticks up as filing flags up to $1.2 bln Q4 upstream hit

Exxon Mobil (XOM) stock ticks up as filing flags up to $1.2 bln Q4 upstream hit

NEW YORK, Jan 9, 2026, 11:39 EST — Regular session Exxon Mobil (XOM) shares rose 0.6% to $123.63 on Friday after the oil major said lower crude prices could cut fourth-quarter upstream earnings — its oil and gas production business — by about $800 million to $1.2 billion. It also said stronger refining margins, the gap between crude costs and fuel prices, could lift earnings by $300 million to $700 million, while restructuring charges may shave about $200 million. Analysts expect adjusted earnings of $1.66 per share; “many brokers, including us, have yet to mark to market,” Scotiabank analysts wrote.
9 January 2026
···
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

New York, Jan 9, 2026, 11:52 EST — Regular session CG Oncology shares jumped on Friday after the company moved up the expected timing for late-stage trial results in bladder cancer. The stock was up 25.1% at $52.45 by 11:52 EST, versus Thursday’s close of $41.93, after trading between $41.63 and $52.64 on the day as volume topped 4.1 million shares. The faster timetable pulls forward a key catalyst for a biotech still in trials. In this part of the market, investors often trade the calendar as hard as the science. Topline data — the first look at whether a
9 January 2026
····
Rocket Lab stock jumps today despite $103 million CFO sale filing: what RKLB traders watch next

Rocket Lab stock jumps today despite $103 million CFO sale filing: what RKLB traders watch next

New York, Jan 9, 2026, 11:43 EST — Regular session Rocket Lab Corp shares rose 4.6% to $86.87 in late morning trading on Friday, bouncing after a dip a day earlier as investors weighed heavy insider selling disclosed in regulatory filings. (MarketBeat) The moves matter because Rocket Lab’s rally into year-end has made the stock sensitive to supply — and headlines — when top executives sell. Shares had fallen 1.2% on Thursday to $83.08, after touching $82.26, MarketBeat data showed. A Form 4 filing showed Chief Financial Officer Adam C. Spice sold 1,365,665 shares on Jan. 5 at weighted-average prices
9 January 2026
··
Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim

Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim

New York, Jan 9, 2026, 11:53 EST — Regular session Liquidia Corp shares jumped nearly 15% in morning trading on Friday after the drugmaker posted preliminary full-year figures for its newly launched pulmonary drug, easing near-term worries about demand and cash use. The move matters because Yutrepia is Liquidia’s main growth engine, and the stock has been trading like a referendum on whether the launch can outrun legal noise and the cost of building a sales force. Early sales traction can reset expectations fast in small-cap biotech, for better or worse. Liquidia said it booked preliminary, unaudited net product sales
9 January 2026
···
Bloom Energy stock jumps again as $2.65B AEP fuel-cell order keeps Wyoming data-center trade in focus

Bloom Energy stock jumps again as $2.65B AEP fuel-cell order keeps Wyoming data-center trade in focus

NEW YORK, Jan 9, 2026, 11:26 EST — Regular session Bloom Energy Corp shares rose 3.6% to $126.23 in late morning trading after hitting an earlier high of $129.96. The session low was $120.62. The move comes after American Electric Power disclosed that its unit will exercise a substantial portion of its option for Bloom’s solid oxide fuel cells — systems that generate electricity on-site from fuel such as natural gas, rather than by burning it in a turbine. AEP also said it has a 20-year agreement with an unnamed customer to take all the output from a fuel-cell generation
9 January 2026
·····
Tecnoglass stock jumps today — what’s driving TGLS after Apogee’s outlook cut

Tecnoglass stock jumps today — what’s driving TGLS after Apogee’s outlook cut

NEW YORK, January 9, 2026, 11:32 ET — Regular session Tecnoglass Inc shares rose 3.4% on Friday, reversing part of this week’s pullback as building-products names found a bid in a stronger U.S. tape. The stock was up $1.74 at $52.97 in late morning trade. The move matters now because traders have been quick to treat any warning from peers as a read-through for commercial construction demand, where orders can turn fast and price pressure shows up before volumes do. Tecnoglass sells heavily into the U.S., so sentiment swings with every hint that projects are slipping. Friday’s bounce also came
9 January 2026
··
GE Vernova stock nudges higher as Baird downgrade flags turbine oversupply fears

GE Vernova stock nudges higher as Baird downgrade flags turbine oversupply fears

NEW YORK, Jan 9, 2026, 11:48 EST — Regular trading GE Vernova (GEV) shares added 0.3% to $630.53 in late morning trading on Friday after Baird downgraded the power-equipment maker and lowered its price target to $649 from $816. Baird analyst Ben Kallo said worries about power capacity oversupply were “shifting sentiment” on the stock. (TipRanks) The move matters because GE Vernova has turned into a crowded trade tied to booming electricity demand from artificial intelligence and other data-heavy uses, squeezing supplies of grid equipment and gas turbines. In December, the company forecast 2026 revenue of $41 billion to $42
9 January 2026
···
1 … 802 803 804 805 806 … 2,714

Stock Market Today

Go toTop